CNS5:Pleomorphic xanthoastrocytoma: Difference between revisions
| [unchecked revision] | [unchecked revision] |
| Line 86: | Line 86: | ||
|Context-dependent ( e.g. For patients with CNS tumors who harbor NTRK fusions, TRK inhibitors such as larotrectinib or repotrectinib are considered a preferred therapy, regardless of histology, if other options are limited) NCCN CNS Cancer guidelines | |Context-dependent ( e.g. For patients with CNS tumors who harbor NTRK fusions, TRK inhibitors such as larotrectinib or repotrectinib are considered a preferred therapy, regardless of histology, if other options are limited) NCCN CNS Cancer guidelines | ||
|Reported in individual cases; more common in glioneuronal/low-grade gliomas | |Reported in individual cases; more common in glioneuronal/low-grade gliomas | ||
|} | |} | ||
==Individual Region Genomic Gain/Loss/LOH== | ==Individual Region Genomic Gain/Loss/LOH== | ||
| Line 119: | Line 110: | ||
|D | |D | ||
|No (however, frequently mentioned in literature as a recurrent copy number change in PXA (PMID: | |No (however, frequently mentioned in literature as a recurrent copy number change in PXA (PMID: | ||
| | |Trisomy, supports diagnosis; also seen in other gliomas | ||
|- | |- | ||
| | |22 | ||
|Loss | |||
| | |Whole chr22 (varied cytoband, arm) | ||
| | |NF2, others | ||
|D | |||
| | |No (not guideline-specific, recurrent in PXA) | ||
|Frequently reported, may occur with other losses | |||
| | |||
| | |||
|- | |- | ||
| | |8p | ||
| | |Loss | ||
| | |chr 8p (varied region) | ||
| | |Varies | ||
| | |P | ||
| | |No | ||
| | |Seen in a subset, less common ((PMID: 28181325) | ||
|} | |} | ||
==Characteristic Chromosomal or Other Global Mutational Patterns== | ==Characteristic Chromosomal or Other Global Mutational Patterns== | ||